# A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma

> **NCT03676946** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Lee's Pharmaceutical Limited** · enrollment: 15 (estimated)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** ZKAB001 5mg/kg
- **DRUG:** ZKAB001 10mg/kg
- **DRUG:** ZKAB001 15mg/kg

## Key facts

- **NCT ID:** NCT03676946
- **Lead sponsor:** Lee's Pharmaceutical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-10
- **Primary completion:** 2020-02-14
- **Final completion:** 2023-06-23
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2018-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03676946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03676946, "A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03676946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*